Having trouble accessing articles? Reset your cache.

A pyrrolopyrimidine-based TYRO3 inhibitor for primary effusion lymphoma

DISEASE CATEGORY: Cancer

INDICATION: Non-Hodgkin lymphoma (NHL)

A UNC Chapel Hill team identified a pyrrolopyrimidine-based inhibitor of TYRO3 that could

Read the full 181 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE